Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastrointestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain and analgesics, respiratory, and vitamins, minerals, and nutrients; and contract development services. The company was incorporated in 1978 and is headquartered in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.

Revenue projections:

Revenue projections for GLAND
Revenue projections for GLAND

Gland Pharma Limited's revenues are expected to fall below last year's, and this forecast tends to raise concerns among investors. A revenue drop can negatively impact the company's profitability, making investors more cautious about their positions due to the risks of declining financial performance.

Financial Ratios:

currentRatio 4.12900
forwardPE 24.25109
debtToEquity 3.16100
earningsGrowth 0.12300
revenueGrowth 0.05800
grossMargins 0.58609
operatingMargins 0.13961
trailingEps 48.04000
forwardEps 65.01000

GLAND's current ratio is 4.129, showing the company's capacity to service its short-term debt through its cash reserves and current assets. This is a positive indicator of liquidity, suggesting GLAND has no trouble covering its short-term financial obligations.
Gland Pharma Limited's Forward PE being in a good range indicates that the stock is valued appropriately based on its earnings. This suggests the stock is not overpriced and leaves room for growth, providing investors with an opportunity for potential appreciation in value.
GLAND's forward EPS exceeds its trailing EPS, indicating that the company is projected to be more profitable in the current financial year compared to the previous one. This suggests positive growth and improved earnings, signaling an optimistic outlook for GLAND's financial performance.

Price projections:

Price projections for GLAND
Price projections for GLAND

Over time, GLAND's price projections have been revised higher, signaling growing confidence in the company's future. This upward trend suggests analysts anticipate strong performance and increased market value for GLAND.

Insider Transactions:

Insider Transactions for GLAND
Insider Transactions for GLAND


There were 3 GLAND sales transactions, at market price of 1928.3332926432292.Throughout the period under consideration, no sell transactions were recorded.The higher number of buys versus sells near Gland Pharma Limited's current price suggests optimism among investors. This buying trend could be interpreted as a sign that the market expects favorable outcomes for the stock in the near future.

Recommendation changes over time:

Recommendations trend for GLAND
Recommendations trend for GLAND


A recent buy bias from analysts toward GLAND may inspire confidence in investors, who could view the stock as a promising investment. This positive sentiment suggests that GLAND might be an appealing option for those looking to grow their wealth through stock market investments.